Disposition and pharmacokinetics of a GalNAc3-Conjugated antisense oligonucleotide targeting human lipoprotein (a) in monkeys

被引：0
作者：
不详
机构：
来源：
CHIMICA OGGI-CHEMISTRY TODAY | 2018年 / 36卷 / 02期
关键词：
Oligonucleotide; phosphorothioate; oligonucleotide conjugate; antisense; GalNAc; lipoprotein; pharmacokinetics; ISIS; 681257;
D O I：
暂无
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：60 / 61
页数：2
相关论文
共 24 条
  • [21] Preclinical and Phase 1 Assessment of Antisense Oligonucleotide Bepirovirsen in Hepatitis B Virus-Transgenic Mice and Healthy Human Volunteers: Support for Clinical Dose Selection and Evaluation of Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses
    Han, Kelong
    Theodore, Dickens
    McMullen, Gina
    Swayze, Eric
    McCaleb, Michael
    Billioud, Gaetan
    Wieland, Stefan
    Hood, Steve
    Paff, Melanie
    Bennett, C. Frank
    Kwoh, T. Jesse
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2022, 11 (10): : 1191 - 1202
  • [22] PHARMACOKINETICS OF A NEW HUMAN MONOCLONAL-ANTIBODY AGAINST CYTOMEGALOVIRUS .3. CORRESPONDENCE OF THE IDIOTYPE ACTIVITY AND VIRUS NEUTRALIZATION ACTIVITY OF THE NEW MONOCLONAL-ANTIBODY, REGAVIRUMAB IN RAT SERUM AND ITS PHARMACOKINETICS IN RATS AND MONKEYS
    ARIZONO, H
    SUGANO, T
    KAIDA, S
    SHIBUSAWA, K
    KARASAWA, Y
    ESUMI, Y
    KONDO, S
    KIYOKI, M
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1994, 44-2 (07): : 909 - 913
  • [23] Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease
    Sadiq, Muhammad Waqas
    Asimus, Sara
    Belvisi, Maria G.
    Brailsford, Wayne
    Fransson, Rebecca
    Fuhr, Rainard
    Hagberg, Anette
    Hashemi, Mahdi
    Jensen, Tina Jellesmark
    Jonsson, Julia
    Keen, Christina
    Koernicke, Thomas
    Kristensson, Cecilia
    Maenpaa, Jukka
    Necander, Sofia
    Nemes, Szilard
    Betts, Joanne
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (01) : 260 - 270
  • [24] Pharmacokinetics, disposition and lipid-modulating activity of 5-{2-[4-(3,4-difluorophenoxy)-phenyl]-ethylsulfamoyl}-2-methyl-benzoic acid, a potent and subtype-selective peroxisome proliferator-activated receptor α agonist in preclinical species and human
    Frederick, K. S.
    Maurer, T. S.
    Kalgutkar, A. S.
    Royer, L. J.
    Francone, O. L.
    Winter, S. M.
    Terra, S. G.
    Chen, D.
    Gao, X.
    XENOBIOTICA, 2009, 39 (10) : 766 - 781
123